Celgene Corporation (CELG) Shares Sold by Macquarie Group Ltd.

Macquarie Group Ltd. reduced its holdings in shares of Celgene Corporation (NASDAQ:CELG) by 4.9% in the first quarter, according to its most recent filing with the SEC. The fund owned 2,480,502 shares of the biopharmaceutical company’s stock after selling 127,809 shares during the period. Macquarie Group Ltd. owned about 0.32% of Celgene Corporation worth $308,649,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of CELG. Douglas Lane & Associates LLC lifted its stake in shares of Celgene Corporation by 3.0% during the 1st quarter. Douglas Lane & Associates LLC now owns 391,993 shares of the biopharmaceutical company’s stock worth $48,776,000 after acquiring an additional 11,419 shares during the last quarter. Hudson Valley Investment Advisors Inc. ADV lifted its stake in shares of Celgene Corporation by 17.2% during the 1st quarter. Hudson Valley Investment Advisors Inc. ADV now owns 20,676 shares of the biopharmaceutical company’s stock worth $2,573,000 after acquiring an additional 3,030 shares during the last quarter. Diversified Trust Co lifted its stake in shares of Celgene Corporation by 0.4% during the 1st quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 9 shares during the last quarter. Westwood Management Corp IL lifted its stake in shares of Celgene Corporation by 102.0% during the 1st quarter. Westwood Management Corp IL now owns 213,330 shares of the biopharmaceutical company’s stock worth $26,545,000 after acquiring an additional 107,700 shares during the last quarter. Finally, V Wealth Management LLC bought a new stake in shares of Celgene Corporation during the 1st quarter worth approximately $1,252,000. 79.43% of the stock is owned by hedge funds and other institutional investors.

Shares of Celgene Corporation (NASDAQ:CELG) traded up 0.14% during mid-day trading on Tuesday, reaching $141.12. The company’s stock had a trading volume of 854,877 shares. The company’s 50-day moving average is $134.21 and its 200-day moving average is $126.84. The stock has a market capitalization of $110.41 billion, a price-to-earnings ratio of 43.70 and a beta of 1.89. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $142.64.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.44 earnings per share. Equities analysts predict that Celgene Corporation will post $7.32 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.thestockobserver.com/2017/09/12/celgene-corporation-celg-shares-sold-by-macquarie-group-ltd.html.

A number of brokerages recently issued reports on CELG. Vetr lowered Celgene Corporation from a “buy” rating to a “hold” rating and set a $145.17 price target for the company. in a research note on Wednesday, September 6th. BTIG Research reissued a “neutral” rating on shares of Celgene Corporation in a research note on Tuesday, September 5th. Cantor Fitzgerald reissued a “buy” rating on shares of Celgene Corporation in a research note on Monday, August 28th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $175.00 price target on shares of Celgene Corporation in a research note on Wednesday, August 9th. Finally, Cann reissued a “buy” rating and set a $175.00 price target on shares of Celgene Corporation in a research note on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and twenty-two have issued a buy rating to the stock. Celgene Corporation currently has an average rating of “Buy” and a consensus price target of $147.31.

In other Celgene Corporation news, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the transaction, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michael D. Casey sold 9,250 shares of the firm’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $125.59, for a total value of $1,161,707.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 263,011 shares of company stock worth $35,078,473. Corporate insiders own 0.95% of the company’s stock.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply